AAPGAscentage Pharma Group Inc.Signing up patients
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Chronic Myeloid Leukemia · CML · CML, Chronic Phase
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 333 (planned)
- Started
- Feb 5, 2024
- Main results expected
- Jun 30, 2027
- Fully finished
- Jul 10, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
24-Week MMR Rate (Part A)
Measured over: 24 weeks
24-Week MMR Rate (Part B)
Measured over: 24 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06423911 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC